Loading
A phase 3 trial of icotinib, ensartinib and benmelstobart in lung cancer, run by The First Affiliated Hospital of Guangzhou Medical University, not yet recruiting.
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations is a phase 3, randomised interventional study registered as NCT06955325 by The First Affiliated Hospital of Guangzhou Medical University, with a registry enrolment figure of 270 participants, started 2025-05 and due to reach its primary completion in 2030-12. Interventions recorded: Icotinib; Rezivertinib; Ensartinib; Benmelstobart. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Disease-Free Survival (DFS). Lung eligibility wording from the registry: "* Primary non-squamous NSCLC confirmed by pathology, with no brain metastases". No results are recorded here; the registry entry is the source.
Shares Ensartinib, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Benmelstobart, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Benmelstobart, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.